Vertex Pharmaceuticals and Entrada Therapeutics, Inc. entered a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development.   Entrada will receive $224 million upfront, as well as an equity investment of $26 million. Entrada is eligible to receive as much as $485 million for certain researc...